EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Miltefosine and emerging Leishmania (Mundinia) in Southeast Asia: Molecular insights, therapeutic challenges, and future strategic implementation

Paul Gabriel Escalera Lerona, Anupop Jitmuang, Patsharaporn Techasintana Sarasombath, Methee Chayakulkeeree, Rawadee Kumlert, Padet Siriyasatien, Alistair C Darby, Kanok Preativatanyou iD

PLOS Neglected Tropical Diseases · 31.07.2026 · 20 (7) · e0014555

DOI: 10.1371/journal.pntd.0014555 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 31.07.2026. Verfasst von Paul Gabriel Escalera Lerona und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Sciences and Biotechnology Program, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Phosphorylcholine, Antiprotozoal Agents, Leishmania, Leishmaniasis. Die Arbeit nennt 192 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thailand Science Research and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Miltefosine, the only oral antileishmanial drug with regulatory approval, has expanded treatment options in several endemic settings but shows variable efficacy across Leishmania species, clinical forms, and host immune contexts. In Southeast Asia, where Leishmania ( Mundinia ) martiniquensis and L. ( M. ) orientalis are increasingly reported, amphotericin B formulations remain the main treatment despite toxicity, relapse, and implementation constraints. This review evaluates miltefosine’s clinical relevance, mechanisms of action, and resistance pathways, with emphasis on Thailand and neighboring Southeast Asian settings. A Thai compassionate-use case using miltefosine with liposomal amphotericin B for refractory L. martiniquensis infection achieved repeated clinical improvement and culture negativity after combination induction, although monotherapy was insufficient to maintain remission in advanced immunosuppression. Evidence from other endemic regions indicates that poor adherence, unregulated access, prolonged subtherapeutic exposure, and inadequate monitoring can reduce treatment durability and favor reduced susceptibility. Mechanistic studies in non- Mundinia species identify transport disruption, lipid and sterol remodeling, mitochondrial stress adaptation, redox buffering, and host-parasite effects as resistance-relevant axes, while regional data raise concern for amphotericin B-associated reduced miltefosine susceptibility in L. martiniquensis . Wider implementation should therefore be linked to species-resolved diagnostics, baseline susceptibility testing, longitudinal phenotype-genotype surveillance, drug stewardship, and One Health monitoring. Miltefosine should be considered a rational but carefully monitored therapeutic addition for emerging Southeast Asian leishmaniasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhosphorylcholineAntiprotozoal AgentsLeishmaniaLeishmaniasisCommunicable Diseases, EmergingHumansAsia, SoutheasternDrug ResistanceAmphotericin BAnimals

Substanzen

miltefosinePhosphorylcholineAntiprotozoal AgentsAmphotericin B

Autor:innen und Institutionen

  • Biomedical Sciences and Biotechnology Program, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Center of Excellence in Vector Biology and Vector‑Borne Disease, Chulalongkorn University, Bangkok, Thailand.
  • Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom.
  • Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Siriraj Integrative Center for Neglected Parasitic Diseases, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.

ORCID-Profile: Kanok Preativatanyou

Förderung

  • Thailand Science Research and Innovation

Zitieren

APA

Lerona, P. G. E., Jitmuang, A., Sarasombath, P. T., Chayakulkeeree, M., Kumlert, R., Siriyasatien, P., Darby, A. C., & Preativatanyou, K. (2026). Miltefosine and emerging Leishmania (Mundinia) in Southeast Asia: Molecular insights, therapeutic challenges, and future strategic implementation. PLOS Neglected Tropical Diseases, 20(7), e0014555. https://doi.org/10.1371/journal.pntd.0014555

Vancouver

Lerona PGE, Jitmuang A, Sarasombath PT, Chayakulkeeree M, Kumlert R, Siriyasatien P, et al. Miltefosine and emerging Leishmania (Mundinia) in Southeast Asia: Molecular insights, therapeutic challenges, and future strategic implementation. PLOS Neglected Tropical Diseases. 2026;20(7):e0014555. doi:10.1371/journal.pntd.0014555

BibTeX
@article{Lerona2026,
  author = {Lerona, Paul Gabriel Escalera and Jitmuang, Anupop and Sarasombath, Patsharaporn Techasintana and Chayakulkeeree, Methee and Kumlert, Rawadee and Siriyasatien, Padet and Darby, Alistair C and Preativatanyou, Kanok},
  title = {Miltefosine and emerging Leishmania (Mundinia) in Southeast Asia: Molecular insights, therapeutic challenges, and future strategic implementation},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2026},
  volume = {20},
  number = {7},
  pages = {e0014555},
  doi = {10.1371/journal.pntd.0014555}
}
Kostenlos starten →